the data channel / research-context only
How BPC-157 Doses Are Expressed in the Research Literature
What was administered, to which species, by which route — read as a console, not a protocol. There is no validated human dosing for BPC-157, and none is offered here.
How BPC-157 Doses Are Expressed in the Research Literature
BPC-157 dosage in the literature is expressed almost entirely as animal figures per unit of body weight — not as human doses. Rodent studies most commonly report doses around 10 microg/kg and 10 ng/kg, and some tendon work went as low as 10 pg per rat [1]. The gastric-ulcer cytoprotection work used 400 ng/kg and 800 ng/kg in rats [4]. These are model parameters chosen to probe a biological effect; they are not dosing guidance and do not translate to a human regimen.
The human dose figures that exist come from three small pilots and are single-administration research doses, not protocols. The intravenous safety pilot used 10 mg then 20 mg by one-hour infusion in two adults [7]; the interstitial-cystitis pilot used a single 10 mg intravesical dose during cystoscopy [9]. Reading these as a personal regimen would be a category error — they are isolated research events in studies designed to test feasibility and safety, not to establish how much anyone should use.
BPC-157 Half-Life and Pharmacokinetics
The 2022 pharmacokinetic study is the anchor for any dose discussion. In rats and dogs, BPC-157 showed linear pharmacokinetics and an elimination half-life of under 30 min, breaking down rapidly into small peptide fragments that join normal amino-acid metabolism [2]. Intramuscular bioavailability was roughly 14-19% in rats and 45-51% in dogs [2].
A sub-30-minute half-life means the intact peptide does not linger in circulation. That short systemic window is one reason the literature leans toward local and frequent dosing in animal designs. It must be read as an animal pharmacokinetic profile — there is no validated human pharmacokinetic study, so half-life, bioavailability, and clearance in humans are not established [8].
Routes Studied: Injection and Other Administration Routes in Research
BPC-157 has been administered by a wide range of routes in research. Injection routes dominate the animal work: intraperitoneal is the most common in rodent studies, with intramuscular, intravenous, and local/intra-lesional delivery also used [1][2]. The three human pilots used intravenous infusion, intravesical instillation, and intra-articular injection respectively [7][9][6]. Intragastric/peroral dosing has been used in animal models, notably in the gastric-ulcer work where intramuscular outperformed intragastric [4].
Across these routes the comparison that recurs is local-or-injected versus oral. The injection routes have the bulk of the supporting animal data; the oral question is open and addressed below. No route has validated human dosing parameters attached to it.
Oral and Peroral BPC-157: The Gastric-Stability Question
The interest in oral BPC-157 comes directly from its name. It is termed a "stable gastric pentadecapeptide" because it is reported to remain stable in human gastric juice, which is unusual and motivates the idea that it might survive oral delivery [2]. Animal studies have used intragastric and peroral routes and reported effects, including in the foundational ulcer model [4].
But reported gastric stability is not the same as demonstrated oral pharmacokinetics. There is no validated human oral pharmacokinetic study for BPC-157 — whether and how much intact peptide reaches systemic circulation after oral dosing in humans is not established [2][8]. The gastric-stability descriptor explains why oral administration is studied; it does not confirm that oral dosing produces the systemic exposure seen with injection.
Storage and reconstitution practices discussed online are research-handling conventions, not validated clinical protocols, and this site does not provide them.